<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Three patients with HIV-associated Kaposi <z:hpo ids='HP_0100242'>sarcoma</z:hpo> were treated with human recombinant granulocyte colony stimulating factor (G-CSF) </plain></SENT>
<SENT sid="1" pm="."><plain>They had <z:hpo ids='HP_0000001'>all</z:hpo> developed <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> during treatment with recombinant interferon-alpha-2a, in two cases combined with <z:chebi fb="0" ids="28445">vincristine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> three patients, there was an obvious rapid stimulation after s.c. injection of 300 or 150 micrograms G-CSF per day; the white blood count reached <z:mpath ids='MPATH_458'>normal</z:mpath> values within only a few days and partial transformation to leucocytosis took place </plain></SENT>
<SENT sid="3" pm="."><plain>After discontinuation of G-CSF, leucocyte counts regressed rapidly to pretreatment levels </plain></SENT>
<SENT sid="4" pm="."><plain>A dose of 150 micrograms of G-CSF twice to three times per week proved to be sufficient to keep the white blood cell count in the <z:mpath ids='MPATH_458'>normal</z:mpath> range allowing the treatment necessary for Kaposi <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>G-CSF therapy had no serious side effects </plain></SENT>
<SENT sid="6" pm="."><plain>One of the patients developed a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-like infiltration in his left upper jaw, which histologically simulated Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and which regressed spontaneously after discontinuation of the G-CSF therapy </plain></SENT>
<SENT sid="7" pm="."><plain>G-CSF plays an important role in the treatment of patients with HIV-associated Kaposi <z:hpo ids='HP_0100242'>sarcoma</z:hpo> and enables combined treatment with <z:chebi fb="15" ids="10110">zidovudine</z:chebi>, interferon, and <z:chebi fb="0" ids="35610">cytostatic</z:chebi> drugs </plain></SENT>
</text></document>